Oral vs. Transdermal Estradiol: Which Is Better for Menopause Hormone Therapy?

Key Takeaways

• Both oral and transdermal estradiol effectively treat menopausal symptoms.
• Oral estradiol may provide greater symptom improvement and favorable effects on cholesterol and vascular health.
• Both oral and transdermal estradiol are effective treatment options. While transdermal estradiol bypasses first-pass liver metabolism, current evidence does not demonstrate the same clotting concerns with bioidentical oral estradiol that have historically been associated with oral conjugated equine estrogen (Premarin). 
• Current evidence does not show a significant difference in estradiol breast cancer risk between oral and transdermal preparations.
• The decision between an estradiol patch vs pill should be individualized.
• There is no single best form of estrogen therapy for every woman.

Menopause is defined as the season in a woman’s life that is marked by the cessation of a menstrual period for at least twelve months at around age 51 (1). With a life expectancy of 81 years of age in the United States, this translates to a woman spending almost 40% of her life with a trajectory of symptoms and declining health (8).  Symptoms can include hot flushes, excessive sweating, vaginal atrophy and dryness, decreased libido, weight gain, mood swings including anxiety and depression, insomnia, weakness and fatigue, blood pressure changes, frequent urination and increased urinary tract infections, myalgias, headaches, and joint pain (1). 

Menopausal and perimenopausal women can experience some or all of these symptoms throughout this season and they are a direct result of declining hormone activity including inhibin, estrogen, progesterone, and testosterone (1). Because of these changes, many women begin exploring hormone replacement therapy options for menopause to improve quality of life and reduce long-term health risks. Among these therapies, estradiol remains one of the most studied and effective options, with significant estradiol benefits in menopause for symptom relief and disease prevention.

• Why Estradiol Replacement Matters in Menopause
• Oral vs. Transdermal Estradiol: What’s the Difference?
• Estradiol Patch vs Pill: Comparing the Evidence
• Estradiol Blood Clot Risk and Breast Cancer Risk: What Does the Evidence Show?
• Which Hormone Replacement Therapy Option for Menopause Is Safer: Oral or Transdermal Estradiol?
• What Is the Best Form of Estrogen Therapy?
• Frequently Asked Questions About Oral vs Transdermal Estradiol
• Conclusion: Oral vs Transdermal Estradiol in Menopause Hormone Therapy
• Ready to learn more about BHRT?

Why Estradiol Replacement Matters in Menopause

In addition to symptoms, estrogen deficiency can lead to increased risks of cardiovascular disease, breast, uterine and colon cancers, osteoporosis, Alzheimer’s disease, insulin resistance, metabolic syndrome and diabetes mellitus (2-6,9,10). 

These risks help explain why estradiol remains one of the most important hormone replacement therapy options for menopause. Beyond symptom management, research continues to demonstrate substantial estradiol benefits in menopause, including support for cardiovascular, metabolic, bone, and cognitive health. 

With clinical evidence being studied with less credence given to observational and associative correlations, bioidentical hormone replacement should be offered to more women during this time to mitigate these symptoms, decrease the incidence of these preventable disease processes, and improve overall quality of life.   

Estradiol (E2) is a key hormone to replace once a diagnosis of menopause has been established. When selecting a compounding pharmacy, use a pharmacy that compounds with bioidentical estradiol instead of synthetic hormones to replace the hormones she naturally made during her youthful years. 

It is not to be confused with the commonly prescribed and FDA-approved synthetic estrogen, conjugated equine estrogen (CEE) derived from a pregnant mare. 

Estradiol can be given via oral, transdermal, or vaginal route. In this article, we will focus on oral vs transdermal estradiol, including the potential advantages, risks, and clinical considerations associated with each method of delivery.

Oral vs. Transdermal Estradiol: What’s the Difference?

Replacement of the deficient estradiol in menopausal women has been shown to improve symptoms in as little as four weeks with even more amelioration at twelve weeks (6). This is very encouraging to patients. 

When studying oral vs transdermal replacement, it was further concluded that women who were selected to receive oral estradiol replacement had better symptom management than the women in the transdermal gel group (6). This is likely due to a difference in estradiol serum concentrations. 

After twelve weeks of treatment, women receiving transdermal estradiol replacement had serum levels near 216 pmol/L whereas the oral group had serum levels of 423 pmol/L (9). This doubling has a greater protective effect when trying to mitigate diseases of aging such as osteoporosis, coronary artery disease and Alzheimer’s disease. 

In the same study, serum Sex Hormone Binding Globulin (SHBG) levels increased by 133% in the oral estradiol group, which may also contribute to symptom improvement (9).

Oral Estradiol Benefits

Symptom management is only part of the benefit of estradiol replacement. 

For many years, the leading cause of death in women has been heart disease (7). To lessen this risk, exogenous estradiol therapy may help, particularly when administered orally. Oral estradiol undergoes first-pass metabolism through the liver, influencing cholesterol synthesis and lipid metabolism. 

Studies have shown women taking oral estradiol experienced reductions in baseline Low-Density Lipoprotein (LDL), lipoprotein (a) (Lp(a)), and increased their High-Density Lipoprotein (HDL) concentrations. This was not seen with transdermal or patch replacement (9).

Additional oral estradiol benefits include improved endothelial function and vascular health. Oral estradiol was found to improve both endothelium-dependent and independent blood flow (9). This increased vascularity may decrease subclinical atherosclerosis and reduce cardiovascular disease risk.

Key oral estradiol benefits may include:

• Strong symptom improvement
• Higher serum estradiol concentrations
• Improved lipid profiles
• Increased SHBG levels
• Enhanced endothelial function

Transdermal Estradiol Benefits

Transdermal estradiol is delivered through the skin via patches, gels, creams, pellets, and sublingual.

Because it bypasses hepatic first-pass metabolism, transdermal delivery has historically been viewed as an alternative for women concerned about reports linking oral estrogen therapy to clotting risk. However, much of that concern originated from studies evaluating oral conjugated equine estrogen (Premarin) rather than bioidentical oral estradiol. As a result, many clinicians prescribe transdermal estradiol based on patient preference, individual risk factors, or to avoid confusion surrounding historical hormone therapy data. 

Additional transdermal estradiol benefits may include:

• Convenient patch, gel, or pellet administration
• An option for women who prefer non-oral therapy
• Avoidance of confusion associated with historical data on oral conjugated equine estrogen

Estradiol Patch vs Pill: Comparing the Evidence

When comparing an estradiol patch vs pill, both delivery methods may effectively replace estrogen deficiency and improve menopausal symptoms. However, important differences exist.

The decision between an estradiol patch vs pill should be individualized based on symptoms, cardiovascular goals, patient preference, and risk factors.

Estradiol Blood Clot Risk and Breast Cancer Risk: What Does the Evidence Show?

Despite this encouraging support in favor of oral estradiol replacement, there are studies that link oral estrogen replacement to an increased risk of venous thromboembolisms (VTE) (3). 

When evaluating estradiol blood clot risk, it is important to recognize that many older studies utilized synthetic conjugated equine estrogens and synthetic progestins rather than bioidentical estradiol. As a result, risk estimates may not accurately reflect bioidentical hormone therapy. 

Some analyses suggest the perceived estradiol blood clot risk may be inflated by combining data from different hormone formulations with different biological effects. 

A key distinction is that many historical concerns about estrogen-associated clotting risk stem from studies evaluating oral conjugated equine estrogen (Premarin), often in women many years beyond menopause, rather than bioidentical oral estradiol. These therapies should not be viewed as interchangeable, as differences in formulation and metabolism may contribute to different clinical outcomes. 

Other studies showed results that were statistically insignificant and therefore should not be counted (3).

Estradiol Breast Cancer Risk

Another commonly discussed concern is estradiol breast cancer risk. 

Contrary to popular belief, a meta-analysis of fourteen studies concluded there was no increased risk for breast cancer with estradiol replacement (3). 

Similarly, a systematic review comparing oral versus transdermal delivery methods and breast cancer risk and no significant difference was seen in estradiol breast cancer risk between routes of administration (3). 

This misguided belief that estradiol replacement leads to an increased breast cancer risk could again be linked to previously studied preparations that contain synthetic progestins, not evidenced in this analysis (3).   

In Godstajn et al. robust review comparing oral versus transdermal preparations, there was no difference in risk when comparing glucose metabolism, breast cancer and cardiovascular disease (3). However it seems generally accepted that due to the confusion listed above with synthetic progestins that do have an increased clotting risk, a transdermal route may be best (3).

Which Hormone Replacement Therapy Option for Menopause Is Safer: Oral or Transdermal Estradiol?

The answer depends on the patient.

Oral estradiol may be preferable when:

• Cardiovascular lipid optimization is desired
• There is no history of clotting disorders
• Strong symptom control is needed

Transdermal estradiol may be preferable when:

• The patient prefers patch or gel delivery
• There is concern about historical misconceptions surrounding oral estrogen therapy

What Is the Best Form of Estrogen Therapy?

There is no single best form of estrogen therapy for every woman.

The decision between oral vs transdermal estradiol should be individualized based on symptom severity, cardiovascular goals, medical history, and patient preference.

Current evidence supports both approaches as effective hormone replacement therapy options for menopause. Oral estradiol may offer unique metabolic and cardiovascular advantages, while transdermal therapy may be preferred in certain higher-risk patients.

Ultimately, the best form of estrogen therapy is the one that safely achieves symptom relief, improves quality of life, and aligns with a patient's individual clinical profile.

Conclusion: Oral vs Transdermal Estradiol in Menopause Hormone Therapy

With so much bias and misinformation, it is imperative to deep dive into the research to assist women through this life changing stage. Bioidentical estradiol replacement is safe for the prevention of disease and for symptom management with oral estradiol as the preferred method of delivery. 

When selecting between oral and transdermal therapy, it is important to distinguish bioidentical oral estradiol from older studies involving conjugated equine estrogen (Premarin). While transdermal estradiol remains a valuable option for women who prefer a non-oral route or are concerned about their history of clotting disorders, current evidence does not support automatically equating bioidentical oral estradiol with the clotting concerns historically associated with Premarin.

Ready to Learn More About BHRT?

If you are interested in learning more about the value and efficacy of BHRT as an alternative to medication-based therapies, please consider our Optimal Medicine Training Series, and start training with us at the first course Mastering the Foundations of BHRT.

References

1. American College of Obstetricians & Gynecologists. The menopause years. 2025.https://www.acog.org/womens-health/faqs/the-menopause-years
2. Cipriano, G.L., Mazzon, E., Anchesi, I.Estrogen receptors: a new frontier in alzheimer’s disease therapy. International Journal of Molecular Sciences. 2024; 25,9077. https://doi.org/10.3390/ijms25169077
3. Goldstajn M, Mikus M, Ferrari F, Bosco M, Uccella S, Noventa M, Torok P, Terzic S, Lagana A, Garzon S. Effects of transdermal versus oral hormone replacement therapy in postmenopause: a systematic review. Archives of Gynecology and Obstetrics. 2023;307(6):1727-1745. PMID: 35713694. https://doi.org/10.1007/s00404-022-06647-5
4. Hodis HN, Mack WJ, Henderson VW, Shoupe D, Budoff MJ, Hwang-Levine J, Li Y. Vascular effects of early versus late menopausal treatment with estradiol. The New England Journal of Medicine. 2016;374(13):1221-1231. PMID: 27028912. https://doi.org/10.1056/NEJMoa1505241
5. Sriprasert, I., Hodis, H., Bernick, B., Mirkin, S., Mack, W. Effects of estradiol dose and serum estradiol levels on metabolic measures in early  and late postmenopausal women in the replenish trial. J Womens Health (Larchmt). 2020;00. https:doi.org//10.1089/jwh.2019.8238
6. Tang R, Xie Z, Ruan X, Zhang Z, Ren M, Wu J, Shu K, Shi H, Xie M, Lv S, Yang X, Chen R, Yu Q. Changes in menopausal symptoms comparing oral estradiol versus transdermal estradiol. Climacteric. 2024;27(2): 171-177. PMID: 37942806. https://doi.org/10.1080/13697137.2023.2273530
7. U.S. Centers for Disease Control and Prevention. Leading causes of death in females. 2024. https://www.cdc.gov/womens-health/lcod/females.html
8. U.S. Centers for Disease Control and Prevention. Life expectancy. 2025. https://www.cdc.gov/nchs/fastats/life-expectancy.htm
9. Vehkavaara S, Hakala-Ala-Pietila T, Virkamaki A, Bergholm R, Ehnholm C, Hovatta O, Taskinen M, Yki-Jarvinen H. Differential effects of oral and transdermal estrogen replacement therapy on endothelial function in postmenopausal women. Circulation. 2000;102(22):2687-2693. PMID: 11094033. https://www.ahajournals.org/doi/10.1161/01.CIR.102.22.2687
10. Yang Z, Hu Y, Zhang J, Xu L, Zeng R, Kang D. Estradiol therapy and breast cancer risk in perimenopausal and postmenopausal women: a systematic review and meta-analysis. Gynecological Endocrinology. 2017;33(2): 87-92. PMID: 27898258. https://doi.org/10.1080/09513590.2016.1248932